Pharmaceuticals

Viral Vector Manufacturing Industry Insights: Market Forecast to 2029

November 7, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Viral Vector Manufacturing Market Expected To Become By 2029 Compared With Its 2025 Level?

The viral vector manufacturing market has experienced rapid expansion in recent years. This market is set to increase from $6.93 billion in 2024 to $8.26 billion in 2025, reflecting a compound annual growth rate (CAGR) of 19.1%. The growth observed in the past can be ascribed to a growing pipeline of gene therapies, successful clinical trials and subsequent approvals, increased investment within the biopharmaceutical sector, and a higher prevalence of genetic disorders.

The viral vector manufacturing market size is projected to experience substantial growth in the upcoming years. It is anticipated to reach $17.42 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 20.5%. This growth during the forecast period is attributed to widening applications in oncology, international collaborations in gene therapy research, the increasing adoption of viral vectors in vaccine development, and ongoing clinical trials and commercialization efforts. Key trends for the forecast period include technological innovations in vector production, the emergence of next-generation vectors, a focus on regulatory compliance and standardization, increased collaborations and partnerships, and the global expansion of manufacturing facilities.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12398&type=smp

What Are The Drivers Pushing New Developments In The Viral Vector Manufacturing Market?

The rising occurrence of cancer and infectious diseases is projected to drive the expansion of the viral vector manufacturing market. An infectious disease describes an illness caused by a virus or its harmful substances, transmitted to a vulnerable host through contact with an infected individual, animal, or object. Cancer encompasses a diverse group of ailments that can originate in any bodily organ or tissue when abnormal cells proliferate uncontrollably, extend beyond their normal limits to infiltrate adjacent organs, and disseminate to other parts of the body. Viral vectors are utilized to produce tumor antigens, which are proteins found on tumor cells, thereby stimulating the body’s immune system to fight cancer. Furthermore, viral vectors have demonstrated their utility as vaccines for numerous infectious illnesses in both pre-clinical and clinical studies. For instance, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that the count of cancer diagnoses in Australia climbed from 160,570 in 2022 to 164,694 in 2023, showcasing a significant increase within that year. This escalating trend underscores the expanding prevalence of cancer across the nation. Additionally, in August 2024, figures released by the UK Health Security Agency, a UK-based executive agency, revealed that in England, the UKHSA recorded 368 measles cases in 2023, representing an almost sevenfold surge from the 53 cases documented in 2022, with the West Midlands contributing 44% and London 33% of these cases, respectively. Consequently, the heightened prevalence of cancer and infectious diseases is fueling the expansion of the viral vector manufacturing market.

How Is The Viral Vector Manufacturing Market Segmented?

The viral vector manufacturing market covered in this report is segmented –

1) By Type: Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, Other Types

2) By Disease: Cancer, Genetic Disorders, Infectious Diseases, Other Diseases

3) By Workflow: Upstream Processing, Downstream Processing

4) By Application: Gene And Cell Therapy Development, Vaccine Development, Biopharmaceutical And Pharmaceutical Discovery, Biomedical Research

5) By End-User: Research Organizations, Biotech And Pharmaceutical Companies, Others End Users

Subsegments:

1) By Adenoviral Vectors: Serotype 5, Serotype 2, Serotype 26

2) By Adeno-Associated Viral Vectors: AAV2, AAV5, AAV8, AAV9, Others

3) By Lentiviral Vectors: HIV-1-Based Lentiviral Vectors, SIV-Based Lentiviral Vectors, Others

4) By Retroviral Vectors: Moloney Murine Leukemia Virus (MoMLV), Gammaretroviral Vectors, Others

5) By Other Types: Sendai Viral Vectors, Vesicular Stomatitis Virus (VSV)-Based Vectors, Measles Virus Vectors, Others

What Key Innovation Trends Are Fueling Advancements In The Viral Vector Manufacturing Market?

Product innovation is emerging as a significant and increasingly adopted trend within the viral vector manufacturing market. Major companies operating in this market are introducing novel product developments to sustain their position. For instance, in August 2022, Merck KGaA, a Germany-based science and technology company, launched its VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform. This platform stands out as one of the first Contract development and manufacturing organizations and technology creators to offer an entire viral vector manufacturing package, including AAV, Lentiviral, CDMO, CTO, and process development. This innovative platform assists biopharmaceutical businesses in shortening the time and expense of process development, while simultaneously accelerating the timeline to clinical manufacture.

Which Leading Companies Dominate The Viral Vector Manufacturing Market Share?

Major companies operating in the viral vector manufacturing market include Sanofi S.A., Thermo Fisher Scientific Inc., Merck Group, FUJIFILM Holdings Corporation, Lonza Group, Catalent Inc., Sartorius AG, Charles River Laboratories International Inc., AGC Biologics, Ultragenyx Pharmaceutical Inc., Novasep Holding SAS, Aldevron LLC, Oxford Biomedica plc, LakePharma Inc., Voyager Therapeutics Inc., Mustang Bio Inc., Regenxbio Inc., VGXI Inc., BioNTech IMFS GmbH, FinVector Oy, Vigene Biosciences Inc., Univercells Technologies, Sirion-Biotech GmbH, Cevec Pharmaceuticals GmbH, Batavia Biosciences BV.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

Which Region Is Projected To Lead The Viral Vector Manufacturing Market During The Forecast Period?

North America was the largest region in the viral vector manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Viral Vector Manufacturing Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12398&type=smp

Browse Through More Reports Similar to the Global Viral Vector Manufacturing Market 2025, By The Business Research Company

Viral Vectors And Plasmid Dna Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

Vector Control Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/vector-control-global-market-report

Bacterial And Plasmid Vector Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bacterial-and-plasmid-vector-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795